Latest Life Biosciences News & Updates

See the latest news and media coverage for Life Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Life Biosciences

Biotechnology company developing cellular rejuvenation therapies

lifebiosciences.com

Headquarters: Boston, United States
Founded year: 2017
Company type: Private company
Number of employees: 25–50

Last updated Today

Latest news about Life Biosciences

In short: Life Biosciences initiated its first Phase 1 clinical trial for ER-100 after securing $80 million in Series D funding and FDA clearance.

Company announcements

June 9 Life Biosciences

Life Biosciences dosed first patient in Phase 1 trial

The trial evaluates ER-100 for optic neuropathies including glaucoma and NAION, targeting root cause of age-related vision loss.

April 27 Life Biosciences

Life Biosciences features in TIME100 Companies list

The recognition highlights their work reversing age-related diseases via epigenetic reprogramming. They remain committed to advancing transformative science.

April 8 Life Biosciences

Life Biosciences secures $80 million Series D financing

Funding supports Phase 1 trial of ER-100 for optic neuropathies and advances Partial Epigenetic Reprogramming platform. Announced April 8, 2026.

March 17 Life Biosciences

Life Biosciences' CSO discusses cellular rejuvenation

Sharon Rosenzweig-Lipson highlights IND clearance for lead therapy advancing to clinic to restore visual function in optic neuropathies.

Media coverage

Today Axios

Longevity medicine's do-or-die moment

If cell reprogramming is successful, it'll be a watershed moment in the study of aging.

June 16 MSN

World's first cell‑rejuvenating therapy given to patient

A Boston company treated its first patient with a therapy intended to allow aging optic nerve cells to behave as though they were young again...

June 9 Wired

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials.

April 13 Cryptopolitan

Life Biosciences begins first human trial to reverse cellular aging

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

Never miss news about Life Biosciences

Track Life Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Life Biosciences competitors & trending companies

Browse news for competitors to Life Biosciences and other trending companies.